REFRACT: A phase 2 trial comparing new treatments to standard treatment in relapsed or refractory follicular lymphoma

This trial is comparing new treatments to standard therapy to see if they have better outcomes in patents with relapsed or refractory follicular lymphoma (FL).

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05848765

Trial aim and background  

The aim of this trial is to find out whether new treatments have better outcomes than standard treatment in patients with FL which has either failed to respond to (refractory) or returned after (relapsed) treatment. Patients will be randomly chosen to receive a new treatment or standard treatment. The standard treatment that they receive will be chosen by their doctor before they enter the trial.

The standard treatments are:

  • RCHOP
  • RCVP
  • Lenalidomide and rituximab
  • Bendamustine and rituximab
  • Obinutuzumab and bendamustine

The experimental treatments are yet to be decided.

Who can enter 

Adults with FL which has relapsed or become refractory to at least one previous treatment, and have disease that requires further treatment may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • The Christie NHS Foundation Trust, Manchester
  • Nottingham University Hospitals NHS Trust, Nottingham

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05848765

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.